Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe

RegulatorypositiveImsidolimabPositive

AI Analysis

Summary

Vanda Pharmaceuticals announced a positive opinion from the EMA for orphan drug designation of imsidolimab for generalized pustular psoriasis, marking recognition of GPP as a distinct rare disease in Europe.

Outcome Details

EMA Positive Opinion for Orphan Drug Designation

Importance:7/10

Sentiment:

0.80

EMAorphan drug designationregulatory milestonedermatologyrare disease

Related Companies

$VNDA

Read the original article

Published by yahoo_finance on July 16, 2026 8:30 PM

Read Original